Chiesi Group Deal History & Licensing Activity
Chiesi Group is a large pharma headquartered in Italy. Over the past three years, Chiesi Group has been involved in 4 licensing and acquisition transactions, with a primary focus on Small Molecules (6 deals). The company currently has 50 active clinical trials, primarily in Autoimmune.
Deals (12mo)
1
Active Trials
50
Top Modality
Small Molecules
Focus Area
Autoimmune
Chiesi Group Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Chiesi Group in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Sebetralstat | KalVista Pharmaceuticals | Small Molecules | Phase 3 | acquisition | Jun 11, 2026 |
| Ekterly | Chiesi | Small Molecules | Unknown | acquisition | Apr 15, 2026 |
Chiesi Group Pipeline Focus
Therapeutic areas and modalities where Chiesi Group is most active based on deal history and clinical trial data.
Therapeutic Areas
Chiesi Group Strategic Signals
Key indicators of Chiesi Group's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Chiesi Group Clinical Pipeline
Chiesi Group has 50 active clinical trials across 6 development phases.
30
Unknown
4
Phase 4
3
Not Applicable
3
Phase 1
4
Phase 2
6
Phase 3
See How Your Asset Matches Chiesi Group's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Autoimmune assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Chiesi Group Licensing & Deal Activity
Chiesi Group is a large pharma company based in Italy that has been actively engaged in licensing transactions across the biopharma landscape. With 4 deals over the past three years, Chiesi Group ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Chiesi Group include Autoimmune (12 deals and trials), Rare Disease (8 deals and trials), Rare Disease (4 deals and trials), and Cardiovascular (4 deals and trials). In terms of modality, Chiesi Group has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Chiesi Group and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Chiesi Group's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.